Skip to main content
. 2023 Aug 30;66(17):12324–12341. doi: 10.1021/acs.jmedchem.3c00845

Figure 1.

Figure 1

(a) Examples of established EGFR inhibitors; (b) depictions of proposed 5FU conjugates with the covalent binding/release process in the EGFR active site; models of bound conformations of (c) pyrimidine- and (d) quinazoline-based conjugates in the EGFR active site based on PDB structures 4ZAU and 4G5J, respectively.